NLS Abbvie

Genmab and AbbVie have announced topline results from the first cohort of the EPCORE NHL-1 clinical trial evaluating epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody. The study cohort includes 157 patients with relapsed/refractory large B-cell lymphoma (LBCL) who received at least two prior lines of systemic therapy, including 38.9 percent who received prior treatment with […]

Linn Mandahl is steering the Scandinavian arm of AbbVie, and in times of both internal and external changes, a strong culture as a platform is her key to success. In 2019, a Scandinavian organization in the global biopharmaceutical company AbbVie was formed. The merge of the Swedish, Danish and Norwegian operations included around 230 employees […]

Karolinska Development announces that its portfolio company BioArctic has entered into a strategically important collaboration with AbbVie, a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications. Parkinson’s disease is the second most-common neurological disease, affecting more than 10 million […]

AbbVie has announced results from a Phase 3 pivotal study demonstrating that HUMIRA (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. These data were presented at the 44(th) Annual European Society for Dermatological Research (ESDR) Meeting in Copenhagen, Denmark. HS, […]

Abbvie presents new, detailed results from its hepatitis C development program. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie’s regimen with ribavirin (RBV) in adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection with compensated liver cirrhosis. Patients […]